Expression of VEGF in endometrial polyps and down - regulation of oral contraceptive

Abstract

Objective To detect the expression of vascular endothelial growth factor (VEGF) in endometrial polyps (EP), to explore its mechanism based on the mechanism of angiogenesis, and to provide experimental evidence for clinical treatment. Methods 30 patients pathologically confirmed as EP who underwent hysteroscopic resection of EP in our hospital from June 2015 to June 2016 were selected as the study group, and 30 patients who underwent hysteroscopy because of infertility and pathologically confirmed as normal endometrium during the same period were selected as the control group. The expression of VEGF in EP tissue and adjacent zone to the EP of the study group, and control group were measured by immunohistochemistry. The study group was treated with drospirenone and ethinylestradiol for 3 cycles, and then the expression of VEGF in the endometrium was detected again. Results The positive expression rate of VEGF: EP tissue (73.33%) > adjacent zone to the EP (46.67%) > normal endometrium (20.00%) (P<0.05). After 3 cycles of COC treatment, the positive expression rate of VEGF in adjacent zone to the EP of EP patients was down-regulated from 46.67% to 16.67% (P<0.05). Conclusions Increased expression of VEGF leading to increased microvascular angiogenesis may be one of the reasons of the formation of EP. COC treatment can reduce the expression of VEGF in endometrial tissue, and thus has a certain role in preventing relapse of EP. Key words: Endometrial polyp; Vascular endothelial growth factor; Oral contraceptive